tiprankstipranks
Trending News
More News >
NEUSOFT XIKANG HOLDINGS INC. (HK:9686)
:9686
Hong Kong Market

NEUSOFT XIKANG HOLDINGS INC. (9686) AI Stock Analysis

Compare
0 Followers

Top Page

HK:9686

NEUSOFT XIKANG HOLDINGS INC.

(9686)

Select Model
Select Model
Select Model
Neutral 48 (OpenAI - 4o)
Rating:48Neutral
Price Target:
HK$1.00
▲(7.53% Upside)
The overall stock score is primarily influenced by financial performance challenges, including declining revenues and negative profit margins. Technical analysis suggests a bearish trend, while valuation reflects ongoing financial struggles. Improvements in free cash flow provide a slight positive outlook.
Positive Factors
Cash Flow Improvement
Positive operating cash flow indicates improved cash generation, enhancing financial flexibility and supporting long-term operations.
Equity Position Improvement
Improved equity position strengthens the balance sheet, providing a more stable financial foundation for future growth.
Diversified Revenue Streams
Diversified revenue streams reduce reliance on a single income source, enhancing resilience against market fluctuations.
Negative Factors
Declining Revenue
Declining revenue indicates challenges in market demand or competitive positioning, which could hinder long-term growth.
Weak Profit Margins
Weak profit margins reflect operational inefficiencies and pricing pressures, impacting profitability and long-term sustainability.
High Debt Levels
High debt levels can strain cash flow and limit financial flexibility, posing risks to long-term financial health.

NEUSOFT XIKANG HOLDINGS INC. (9686) vs. iShares MSCI Hong Kong ETF (EWH)

NEUSOFT XIKANG HOLDINGS INC. Business Overview & Revenue Model

Company DescriptionXikang Cloud Hospital Holdings, Inc. engages in the development of a city-specific cloud hospital platform. It operates through the following segments: Cloud Hospital Platform Services, Internet Medical Services, Health Management Services, and Smart Healthcare Products. The Cloud Hospital Platform Services segment offers technology solutions to local governments, medical institutions, and insurers. The Internet Medical Services segment includes online hospital, remote medical, smart family doctor, and internet home care services. The Health Management Services segment consists of comprehensive health management and chronic disease management services. The Smart Healthcare Products segment sells smart healthcare products to local governments, primary medical institutions, corporations, and individuals. The company was founded on May 12, 2011 and is headquartered in Shanghai, China.
How the Company Makes MoneyNEUSOFT XIKANG generates revenue through multiple streams, primarily from the sale of healthcare information technology solutions and software services. Key revenue sources include licensing fees for software products, maintenance and support services, and consulting services related to system integration and implementation. Additionally, the company earns income from partnerships with healthcare institutions and government projects, which often involve large-scale system deployments and upgrades. The growing demand for digital healthcare solutions further contributes to the company's earnings, as more healthcare providers seek to improve operational efficiencies and patient care through technology.

NEUSOFT XIKANG HOLDINGS INC. Financial Statement Overview

Summary
The company is facing financial challenges with declining revenues and negative profit margins. High leverage and negative return on equity indicate financial instability, although free cash flow growth suggests some operational efficiencies.
Income Statement
45
Neutral
The company has experienced declining revenue over the past periods, with a negative revenue growth rate of -6.1% in the TTM. Gross profit margin remains moderate at 28.8%, but net profit margin is negative, indicating ongoing losses. EBIT and EBITDA margins are also negative, reflecting operational challenges.
Balance Sheet
40
Negative
The company has a high debt-to-equity ratio of 1.62, indicating significant leverage. Return on equity is negative, suggesting that the company is not generating profits from its equity base. The equity ratio is low, pointing to potential financial instability.
Cash Flow
55
Neutral
Free cash flow has shown growth of 25.3% in the TTM, which is a positive sign. The operating cash flow to net income ratio is low, but the free cash flow to net income ratio is above 1, indicating that the company is generating cash despite net losses.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue500.89M501.50M537.72M687.41M614.30M503.01M
Gross Profit144.25M147.50M164.61M168.45M170.23M134.11M
EBITDA-45.88M-52.06M-75.65M-161.41M-214.71M-101.65M
Net Income-72.38M-83.05M-154.65M-241.97M-296.54M-196.43M
Balance Sheet
Total Assets1.11B1.26B1.40B934.45M946.85M954.64M
Cash, Cash Equivalents and Short-Term Investments703.42M797.70M822.67M351.76M364.91M419.87M
Total Debt520.84M574.47M603.44M573.44M456.28M446.23M
Total Liabilities785.76M892.31M964.28M1.38B1.21B1.09B
Stockholders Equity322.38M363.31M428.14M-451.98M-274.55M-132.99M
Cash Flow
Free Cash Flow36.20M21.56M-24.42M-81.17M-101.77M-124.13M
Operating Cash Flow35.91M21.56M-20.16M-73.83M-83.38M-17.30M
Investing Cash Flow-30.55M110.45M-146.60M-8.45M-5.47M-195.16M
Financing Cash Flow-93.62M-56.56M504.77M64.62M64.90M216.29M

NEUSOFT XIKANG HOLDINGS INC. Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price0.93
Price Trends
50DMA
0.95
Negative
100DMA
0.97
Negative
200DMA
0.92
Positive
Market Momentum
MACD
-0.01
Positive
RSI
44.78
Neutral
STOCH
33.88
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9686, the sentiment is Neutral. The current price of 0.93 is below the 20-day moving average (MA) of 0.95, below the 50-day MA of 0.95, and above the 200-day MA of 0.92, indicating a neutral trend. The MACD of -0.01 indicates Positive momentum. The RSI at 44.78 is Neutral, neither overbought nor oversold. The STOCH value of 33.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:9686.

NEUSOFT XIKANG HOLDINGS INC. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
72
Outperform
HK$24.24B41.9424.57%0.67%13.58%24.59%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
48
Neutral
HK$757.69M-10.03-20.43%
44
Neutral
HK$588.08M-2.23-20.60%11.43%4.88%
43
Neutral
HK$2.68B513.640.22%-4.38%
40
Neutral
HK$1.12B-6.07-12.97%-32.17%-1.20%
39
Underperform
HK$4.58B-54.80-2.23%-4.99%47.18%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:9686
NEUSOFT XIKANG HOLDINGS INC.
0.93
-0.07
-7.00%
HK:2158
Yidu Tech, Inc.
4.97
-0.19
-3.68%
HK:2160
MicroPort CardioFlow Medtech Corp.
1.13
0.48
73.85%
HK:2170
Suzhou Basecare Medical Corp. Ltd. Class H
2.10
-0.61
-22.51%
HK:2251
Beijing Airdoc Technology Co. Ltd. Class H
11.37
-0.59
-4.93%
HK:2276
Shanghai Conant Optical Co. Ltd. Class H
53.25
35.53
200.51%

NEUSOFT XIKANG HOLDINGS INC. Corporate Events

Xikang Cloud Hospital Holdings Reports Improved Losses Amid Revenue Dip
Aug 27, 2025

Xikang Cloud Hospital Holdings Inc. announced its interim results for the first half of 2025, reporting a slight revenue decrease of 0.3% compared to the same period in 2024, with a total revenue of RMB178.6 million. Despite the revenue dip, the company reduced its net loss by 17.4% to RMB50.0 million, attributed to business optimization and resource allocation improvements. The company’s unique business model, which involves strategic collaboration with local governments, aims to enhance the regional digital healthcare ecosystem through AI-driven innovations and scalable cloud hospital platforms.

The most recent analyst rating on (HK:9686) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on NEUSOFT XIKANG HOLDINGS INC. stock, see the HK:9686 Stock Forecast page.

Xikang Cloud Hospital Holdings to Discuss Interim Results and Dividend
Aug 15, 2025

Xikang Cloud Hospital Holdings Inc. has announced a board meeting scheduled for August 27, 2025, to discuss and approve the interim results for the first half of the year ending June 30, 2025. The meeting will also consider the recommendation of an interim dividend, indicating a potential financial distribution to shareholders, which could impact investor sentiment and the company’s market positioning.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 31, 2025